SB 1407, the “Anyone But China Safe Drug Act” or “ABC Safe Drug Act,” would restrict federal health programs from purchasing drugs whose active pharmaceutical ingredients are manufactured in the People’s Republic of China. Beginning January 1, 2028, covered federal agencies and programs could buy only drugs with at least 60 percent of active ingredients manufactured in qualifying countries other than China; beginning January 1, 2030, the requirement would rise to 100 percent. The bill defines qualifying countries as those outside China that also meet FDA health and safety standards, and it authorizes HHS to issue temporary waivers for programs unable to comply until January 1, 2031.
The bill also amends the Federal Food, Drug, and Cosmetic Act to require drug labeling to specify the country of origin of each active ingredient. In addition, it creates a temporary tax incentive by allowing 100 percent expensing for certain pharmaceutical and medical device manufacturing property placed in service in the United States between the end of 2024 and the end of 2030, with the goal of encouraging domestic manufacturing capacity for drugs and devices.
If enacted, the bill would affect federal purchasing rules for HHS, VA, DOD, and other federal health care programs, and it would likely influence supply chains, procurement standards, and labeling practices across the pharmaceutical sector. It would also amend the Internal Revenue Code to provide accelerated depreciation for qualifying manufacturing investments, potentially benefiting companies that expand or build U.S.-based drug and device production facilities.
Because there are no recorded committee transcripts or votes in the provided materials, the available sentiment is limited to the bill’s structure and framing. The bill is clearly designed to reduce reliance on Chinese pharmaceutical inputs and to promote domestic or non-Chinese supply chains, suggesting support from lawmakers focused on national security, supply-chain resilience, and industrial policy. At the same time, the mandatory sourcing thresholds and labeling requirements could draw concern from stakeholders worried about drug availability, compliance costs, and the feasibility of rapidly shifting complex global supply chains.
The main points of contention are likely to be the strict sourcing mandates, the practicality of verifying the origin of active ingredients, and the risk of disruptions to federal drug purchasing. Supporters would likely emphasize reducing dependence on China and strengthening U.S. manufacturing, while critics may argue that the bill could increase costs, limit supplier options, and create implementation challenges for federal health programs and manufacturers.
The bill would amend federal procurement rules for drugs purchased by major federal health programs, including HHS, VA, DOD, and other federal health care programs, by imposing phased restrictions on drugs with active pharmaceutical ingredients manufactured in China. It would also amend the Federal Food, Drug, and Cosmetic Act to require country-of-origin labeling for each active ingredient and would temporarily expand 100 percent expensing under the Internal Revenue Code for qualifying pharmaceutical and medical device manufacturing property placed in service in the United States through 2030.
No committee debate or vote record was provided, so there is no direct evidence of legislative sentiment from hearings or roll calls. Based on the bill text, the measure appears to be framed positively by its sponsor as a supply-chain security and domestic manufacturing initiative, likely appealing to supporters of reducing dependence on China. Potential opposition would likely come from stakeholders concerned about implementation, drug access, and compliance burdens.
The likely areas of contention are the feasibility and cost of excluding Chinese-manufactured active ingredients from federal purchasing, the ability of manufacturers and agencies to document ingredient origin, and whether the phased deadlines are realistic. Supporters are likely to be lawmakers and industry advocates favoring domestic production and national-security-driven sourcing rules, while critics may include health care purchasers, manufacturers, and others concerned about supply disruptions, higher prices, and administrative complexity.